The introduction of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors has led to major improvements in the use of maintenance therapy for women with advanced high-grade serous ovarian cancer [10]. The gene discussed is PARP1; the disease is ovarian serous adenocarcinoma.